Lv5
1520 积分 2021-03-29 加入
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialZolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
4小时前
待确认
Prediction of creatinine clearance from serum creatinine
8个月前
已完结
Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers
10个月前
已完结
Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies
10个月前
已完结
31909927
10个月前
已关闭
Acute kidney injury after CAR-T cell infusion
10个月前
已完结
Latent human herpesvirus 6 is reactivated in CAR T cells
11个月前
已完结
Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy
11个月前
已完结
Disseminated tuberculosis infection in a CAR T-cell recipient
11个月前
已完结
New Onset of Tuberculosis Complicating FDG PET/CT Evaluation in Patient With Recent Chimeric Antigen Receptor T-Cell Therapy
11个月前
已完结
皖公网安备34019202002308
